Find, compare & contact
Propentofylline
API Manufacturers & Suppliers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Looking for Propentofylline API 55242-55-2?
- Description:
- Here you will find a list of producers, manufacturers and distributors of Propentofylline. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
- API | Excipient name:
- Propentofylline
- Synonyms:
- Cas Number:
- 55242-55-2
- DrugBank number:
- DB06479
- Unique Ingredient Identifier:
- 5RTA398U4H
General Description:
Propentofylline is a chemical compound identified by the CAS number 55242-55-2. It is known for its distinct pharmacological properties and applications.
Indications:
This drug is primarily indicated for: Investigated for use/treatment in alzheimer's disease. Its use in specific medical scenarios underscores its importance in the therapeutic landscape.
Mechanism of Action:
Propentofylline functions by: Propentofylline is a xanthine derivative and phosphodiesterase inhibitor with purported neuroprotective effects. It inhibits both phosphodiesterase and adenosine uptake. Phosphodiesterase has shown to associated with age-related memory impairment and Alzheimer's disease. β-Amyloid protein 1–42 (β42) can induce apoptosis in the cultured hippocampal neurons, suggesting that it plays an important role in causing neurodegeneration in Alzheimer's disease. Propentofylline is also capable of activating a cAMP–PKA system, depressing the caspase cascade and modifying Bcl-2 family proteins. Propentofylline blocked both the apoptotic features induced by β42 and further induced an anti-apoptotic protein, Bcl-2. It suggests that the protection of propentofylline on the β42-induced neurotoxicity is caused by enhancing anti-apoptotic action through cAMP–PKA system. This mechanism highlights the drug's role in inhibiting or promoting specific biological pathways, contributing to its therapeutic effects.
Classification:
Propentofylline belongs to the class of organic compounds known as xanthines. These are purine derivatives with a ketone group conjugated at carbons 2 and 6 of the purine moiety, classified under the direct parent group Xanthines. This compound is a part of the Organic compounds, falling under the Organoheterocyclic compounds superclass, and categorized within the Imidazopyrimidines class, specifically within the Purines and purine derivatives subclass.
Categories:
Propentofylline is categorized under the following therapeutic classes: Alkaloids, Anti-Ulcer Agents, Central Nervous System Agents, Compounds used in a research, industrial, or household setting, Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 Substrates, Heterocyclic Compounds, Fused-Ring, Nervous System, Neuroprotective Agents, Protective Agents, Psychoanaleptics, Psychostimulants, Agents Used for ADHD and Nootropics, Purines, Purinones, Xanthine derivatives. These classifications highlight the drug's diverse therapeutic applications and its importance in treating various conditions.
Propentofylline is a type of Central Nervous System Agents
Central Nervous System (CNS) Agents are a crucial category of pharmaceutical Active Pharmaceutical Ingredients (APIs) that specifically target the central nervous system. The CNS encompasses the brain and spinal cord, playing a vital role in regulating and controlling various bodily functions, including cognition, movement, emotions, and sensory perception. These agents are designed to interact with specific receptors, enzymes, or ion channels within the CNS to modulate neural activity and restore normal functioning.
CNS agents comprise a diverse range of pharmaceutical APIs, including analgesics, anesthetics, antipsychotics, sedatives, hypnotics, anti-epileptics, and antidepressants. Each subcategory addresses distinct neurological disorders and conditions. For instance, analgesics alleviate pain by targeting receptors in the brain and spinal cord, while antipsychotics are employed to manage psychosis symptoms in mental illnesses such as schizophrenia.
The development of CNS agents involves rigorous research, molecular modeling, and extensive clinical trials to ensure safety, efficacy, and specific target engagement. Pharmaceutical companies invest significant resources in identifying novel drug targets, synthesizing new compounds, and optimizing their pharmacological properties. These agents undergo rigorous regulatory evaluations and must adhere to stringent quality standards and guidelines.
Given the prevalence of CNS disorders globally, the market demand for effective CNS agents is substantial. The development of innovative CNS APIs not only improves patient outcomes but also provides valuable commercial opportunities for pharmaceutical companies. Continued advancements in CNS agent research and development hold the promise of groundbreaking therapies that can improve the quality of life for individuals affected by neurological conditions.
